601 / 1119
•
Hematological toxicities in CRT pts
- Gr 1 : 23%
- Gr 2 : 33%
-
Gr 3 : 25% (Vs 31% RTOG 9708 p = NS)
•
Median V 10 : 96%; V20: 84%
•
Median V 30 : 61%; V40: 37%
•
V40 >37% : 75% had Gr>2 Vs 40%
•
Grade 4 toxicity : 0% Vs 13% (RTOG 9708)
Conclusions: Pelvic IMRT with weekly cisplatin is associated with low rates of HT and
high rates of weekly cisplatin use. The volume of bone marrow receiving 40 Gy and the
median dose to bone marrow correlated with higher rates of grade 2 toxicity among
patients receiving weekly cisplatin (cervical cancer patients). Evaluation and limitation of
the volume of bone marrow treated with pelvic IMRT is warranted in patients receiving
concurrent chemotherapy
IJROBP 2013
V 40 Gy > 40% correlated with > grade 2 HT toxicity
Mahantshetty et al; IJGC 2012